Carbonic Anhydrase IX as an Anticancer Therapy Target: Preclinical Evaluation of Internalizing Monoclonal Antibody Directed to Catalytic Domain

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|16|29|3255-3263

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.16, Iss.29, 2010-10, pp. : 3255-3263

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Carbonic Anhydrase IX as a Target for Designing Novel Anticancer Drugs

By  

Current Medicinal Chemistry, Vol. 19, Iss. 6, 2012-02 ,pp. : 821-830

Bentham Science Publishers

Access to resources Recommend Favorite

Novel antibody to a carbonic anhydrase: patent evaluation of WO2011138279A1

By Winum Jean-Yves  

Expert Opinion on Therapeutic Patents, Vol. 23, Iss. 6, 2013-06 ,pp. : 757-760

Informa Healthcare

Access to resources Recommend Favorite

Antibody Directed Enzyme Prodrug Therapy (ADEPT) and Related Approaches for Anticancer Therapy

By  

Mini Reviews in Medicinal Chemistry, Vol. 1, Iss. 4, 2001-11 ,pp. : 399-407

Bentham Science Publishers

Access to resources Recommend Favorite

uPAR as Anti-Cancer Target: Evaluation of Biomarker Potential, Histological Localization, and Antibody-Based Therapy

By  

Current Drug Targets, Vol. 12, Iss. 12, 2011-11 ,pp. : 1744-1760

Bentham Science Publishers

Access to resources Recommend Favorite

Monoclonal Antibody-Directed Cytotoxic Therapy: Potential in Malignant Diseases of Aging

By Panousis C.   Pietersz G.A.  

Drugs & Aging, Vol. 15, Iss. 1, 1999-07 ,pp. : 1-13

Adis International

Access to resources Recommend Favorite